Stock Price Quote

RUBICON RESEARCH LTD.

NSE : RUBICONBSE : 544578ISIN CODE : INE506V01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE1516.20-3.25 (-0.21 %)
PREV CLOSE ( ) 1519.45
OPEN PRICE ( ) 1517.20
BID PRICE (QTY) 1513.95 (15)
OFFER PRICE (QTY) 1516.70 (2)
VOLUME 2069
TODAY'S LOW / HIGH ( )1482.40 1519.15
52 WK LOW / HIGH ( )571 1896.15
NSE1514.90-8.5 (-0.56 %)
PREV CLOSE( ) 1523.40
OPEN PRICE ( ) 1513.90
BID PRICE (QTY) 1514.90 (15)
OFFER PRICE (QTY) 1515.60 (4)
VOLUME 17979
TODAY'S LOW / HIGH( ) 1483.40 1519.90
52 WK LOW / HIGH ( )570.75 1899
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 06-05 1999
Management Info
Venkat Changavalli - Chairman Pratibha Pilgaonkar - Managing Director
Registered Office

Address Medone House, B-75,Road No. 33,Wagle Estate, Thane (West),
Thane,
Maharashtra-400604

Phone 022- 61414000 / 50414000

Email secretarial@rubicon.co.in / reachus@rubicon.co.in

Website www.rubicon.co.in

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

10Oct USFDA completes unannounced inspection
United States Food and Drug Administration (USFDA) has completed an unan..
29Aug Rubicon Research informs about disclos
Rubicon Research has informed thatit encloseddisclosure under Regulation..
27Aug Rubicon Research informs about disclo
Rubicon Research has informed that the exchange has received the disclos..
27Aug General Atlantic sells 8.4% stake in R
The US-based global investment firm General Atlantic, through its affili..
23Jul Rubicon Research soars on acquiring ma
Rubicon Research is currently trading at Rs. 1515.00, up by 50.10 points..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit824.491881.65
Gross Profit 1106.57 2527.79
Operating Profit 1272.383214.87
Net Sales 4277.313060.82

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26000.00 (1.21%)
M.Cap ( in Cr)54588.08
Jenburkt Pharma (BSE)
peergroup  997.50 (8.72%)
M.Cap ( in Cr)404.92
Symbiotec Pharmalab (BSE)
peergroup  1219.15 (3.92%)
M.Cap ( in Cr)7538.21
Fredun Pharma (BSE)
peergroup  1522.40 (3.04%)
M.Cap ( in Cr)2523.96
Concord Biotech (BSE)
peergroup  1387.90 (1.44%)
M.Cap ( in Cr)14313.59

Shareholding Pattern

MUTUAL FUNDS/UTI 7.23%
PROMOTERS 59.76%
NON-INSTITUTION 23.3%
FI/BANKS/INSURANCE 0.18%
GOVERNMENT 0%
FII 0%

About Rubicon Research Ltd.

Rubicon Research Ltd. was incorporated in the year 1999. Its today's share price is 1516.2. Its current market capitalisation stands at Rs 25152.84 Cr. In the latest quarter, company has reported Gross Sales of Rs. 13060.82 Cr and Total Income of Rs.13169.14 Cr. The company's management includes Varun Talukdar, Shantanu Rastogi, Pradnya Saravade, Milind Patil, K G Ananthakrishnan, Venkat Changavalli, Parag Suganchand Sancheti, Pratibha Pilgaonkar, Deepashree Tanksale.

It is listed on the BSE with a BSE Code of 544578 , NSE with an NSE Symbol of RUBICON and ISIN of INE506V01022. It's Registered office is at Medone House, B-75,Road No. 33,Wagle Estate, Thane (West)Thane-400604, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BBSR & Co, BSR & Co, BSR & Co LLP, Deloitte Haskins & Sells LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.